February 01, 2015 5:25 AM ET


Company Overview of Cocrystal Pharma, Inc.

Company Overview

Cocrystal Pharma, Inc., a preclinical-stage biopharmaceutical company, intends to develop medicines for use in treating human viral diseases. The company focuses on developing inhibitors of viral replication enzymes that are essential to viral replication. It is developing antiviral therapeutics for human diseases, including Hepatitis C virus, Influenza virus, Rhinovirus, Dengue Virus, and Norovirus. The company also develops targeted in-house chemical libraries consisting of antiviral compounds of various types, including non-nucleoside inhibitors, metal-binding inhibitors, and fragments. In addition, it is developing compounds that inhibit HCV helicase, an enzyme that is essential for hepa...

19805 North Creek Parkway

Bothell, WA 98011

United States

Founded in 2007



Key Executives for Cocrystal Pharma, Inc.

Cocrystal Pharma, Inc. does not have any Key Executives recorded.

Cocrystal Pharma, Inc. Key Developments

Cocrystal Pharma, Inc. Proposes Amendments to the Company's Certificate of Incorporation

Cocrystal Pharma, Inc. proposed at its EGM to be held on March 3, 2015, the shareholders to be approved that the amendments to the company's Certificate of Incorporation to increase the number of authorized shares of common stock from 200 million to 800 million shares.

Cocrystal Pharma, Inc. Announces Resignation of Roger Kornberg and Sam Lee from the Board of Directors

Cocrystal Pharma, Inc. announced that on November 22, 2014, Dr. Roger Kornberg and Dr. Sam Lee resigned from the board of directors of the company.

Cocrystal Pharma, Inc. Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2014

Cocrystal Pharma, Inc. reported financial results for the third quarter and nine months ended September 30, 2014. During the three months period ended September 30, 2014, the company had a loss from operations of $1.2 million. During the nine months period ended September 30, 2014, the company had a loss from operations of $4.1 million. Cash used in operating activities was approximately $4.2 million for the nine months ended September 30, 2014.

Similar Private Companies By Industry

Company Name Region
Adheron Therapeutics, Inc. United States
MPM Medical, Inc. United States
Optimer Pharmaceuticals, Inc. United States
Beneficial Nutraceuticals United States
Apex Fitness, Inc. United States

Recent Private Companies Transactions

November 25, 2014
RFS Pharma, LLC
June 27, 2014
Muscle Pharm Corp.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Cocrystal Pharma, Inc., please visit www.cocrystalpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.